Aripiprazole versus haloperidol treatment in early-stage schizophrenia

Abstract We conducted a secondary analysis of a completed study of the differential efficacy and side effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a subpopulation of patients which does not include first episode or chronic patients. A subpopulation of 360 individual...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychiatric research 2011-06, Vol.45 (6), p.756-762
Main Authors: Girgis, Ragy R, Merrill, David B, Vorel, Stanislav R, Edward Kim, Kimberly Portland, You, Min, Pikalov, Andrei, Whitehead, Richard, Lieberman, Jeffrey A
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adult and adolescent clinical studies
Aged
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotic drugs
Aripiprazole
Biological and medical sciences
Clinical trial
Dose-Response Relationship, Drug
Early-stage
Efficacy
Female
Haloperidol
Haloperidol - administration & dosage
Haloperidol - adverse effects
Humans
Male
Medical sciences
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Piperazines - administration & dosage
Piperazines - adverse effects
Psychiatric Status Rating Scales
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Quinolones - administration & dosage
Quinolones - adverse effects
Response rate
Schizophrenia
Schizophrenia - drug therapy
Schizophrenic Psychology
Severity of Illness Index
Side effects
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We conducted a secondary analysis of a completed study of the differential efficacy and side effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a subpopulation of patients which does not include first episode or chronic patients. A subpopulation of 360 individuals with ESS were identified from a randomized, multi-center, double-blind study of 1294 individuals with schizophrenia at different stages of illness who were randomized to treatment with aripiprazole (ESS = 237) or haloperidol (ESS = 123) for one year. The primary outcome measure was response rate based on a 50% reduction of Positive and Negative Syndrome Scale (PANSS) total scores. Secondary outcomes included several efficacy and safety measures, as well as treatment discontinuation. More individuals in the aripiprazole group (48%) than in the haloperidol group (28%; p  
ISSN:0022-3956
1879-1379
DOI:10.1016/j.jpsychires.2010.09.003